차바이오그룹 뉴스룸

• Kim to oversee cell and gene therapy (CGT) manufacturing operations, processes, operations, and business strategy as CEO during period of rapid expansion across US and Korea

College Station, Texas – January 31, 2024 – Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) of cell and gene therapies (CGTs), today announced the appointment of Paul Kim as chief executive officer (CEO). 

As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands both its capacity and capability in the U.S. and Korea. Yun Jeong Song, outgoing president and CEO, will take her new role as a CEO of Matica Holdings, overseeing the overall global expansion.

Kim brings to Matica Bio nearly three decades of experience across CDMO, CRO and R&D Biopharma sectors as CEO, Managing Director, Chief Business Officer, Managing Partner and Executive Board at WCCT Global, Genopis, Cobra Biologics, Cognate BioServices, and Novartis Venture Fund. Kim led first global pharmacetuical fund focusing on innvative Asian biotech investments at Norvartis Venture Fund. Kim is also the founder of Forward Equity Partners (Formerly Medivate Partners), a private equity firm devoted to healthcare and life sciences investments – the first global healthcare private equity fund to be based in Korea. Specializing in gene and cell therapy, he has invested in over 10 global biotechs and 4 CDMOs so far. He currently serves on the Boards of SCAI Therapeutics, and Riva Therapeutics in San Diego. Kim earned his bachelor’s degree in molecular cell biology from University of California, Berkeley.

“Matica Bio’s bespoke approach to CGT manufacturing at its purpose-built GMP facility is perfectly suited to successfully manufacture cell and gene therapies, unlike any other in the CDMO industry today,” said Kim. “Together with great scientific experts in-house, I look forward to propelling Matica Bio forward during such a pivotal time for the company and the CGT industry at large.”

Kim’s appointment as CEO of Matica Bio is the latest in a series of strategic milestones that the company has announced. Last year, Matica Bio established its board of advisors and expanded its leadership team. The company also optimized several critical components for efficient CGT manufacturing process, including not limited to its fully closed system approach, 100% single-use platform, advanced analytical capabilities and launch of its high performance proprietary cell line, MatiMax^TM.

About Matica Biotechnology, Inc.
Matica Biotechnology, Inc. (Matica Bio) is a CDMO specializing in fully integrated cell and gene therapy manufacturing. The industry-leading experts at our state-of-the-art facility in Texas, deliver breakthrough therapies rapidly and safely through innovative manufacturing solutions. To learn more about Matica Bio, Please visit www.maticabio.com.